During selection for methotrexate resistance, tumorigenic CHEF/16 cells and derivatives from CHEF/16 tumors underwent amplification of the dihydrofolate reductase gene (DHFR) at accelerated rates compared with closely related nontumorigenic CHEF/18 cells. "Dot blot" analysis showed that the CHEF/16 cells contained many more copies of the DHFR gene than did the CHEF/18 cells, when assayed at similar elevated levels of methotrexate resistance. Chromosome analysis ofcell samples taken at several time points during amplification revealed large differences between the nontumorigenic CHEF/18 cells and the two tumorigenic cell lines. The tumorigenic cells developed few chromosome rearrangements over a 4-log increase in methotrexate resistance, other than increased length
ABSTRACT
During selection for methotrexate resistance, tumorigenic CHEF/16 cells and derivatives from CHEF/16 tumors underwent amplification of the dihydrofolate reductase gene (DHFR) at accelerated rates compared with closely related nontumorigenic CHEF/18 cells. "Dot blot" analysis showed that the CHEF/16 cells contained many more copies of the DHFR gene than did the CHEF/18 cells, when assayed at similar elevated levels of methotrexate resistance. Chromosome analysis ofcell samples taken at several time points during amplification revealed large differences between the nontumorigenic CHEF/18 cells and the two tumorigenic cell lines. The tumorigenic cells developed few chromosome rearrangements over a 4-log increase in methotrexate resistance, other than increased length of a single chromosome, which was shown by in situ hybridization to contain most or all of the amplified DHFR gene copies. In contrast, the CHEF/18 cells underwent complex, progressive changes in almost every chromosome, and in situ hybridization suggested a dispersed pattern of gene amplification. The data support the hypothesis that unregulated amplification is a pathological process, occurring readily in neoplastic but rarely in normal cells, that together with other chromosomal disturbances contributes to the rapid evolution and progression of cancer.
Cancer is a disease of the genome (1, 2) . Progression to increasingly malignant cellular phenotypes and to increasing drug resistance are two major characteristics of neoplastic cells (3) . Underlying these characteristics is the property of genomic instability, a cellular hallmark of cancer (4) .
Genomic instability is manifested as a constellation of chromosomal aberrations including aneuploidy, translocations, point mutations, deletions, duplications, and amplification of localized discrete chromosomal segments. Certain rearrangements, deletions, and trisomies are characteristically associated with particular forms of cancer and are referred to as nonrandom chromosomal changes. Other changes appear to be random. In advanced neoplasias, both random and nonrandom rearrangements are found. As tumors develop and metastasize, continuing genomic changes provide the basis for tumor-cell heterogeneity, drug resistance, and the natural selection of ever more malignant cell types (5) . Thus tumor progression is a highly accelerated evolutionary process, which occurs not over billions of years but within a single human lifetime. To understand how tumors arise, we need to identify and understand the mechanisms that drive this accelerated evolution.
No molecular mechanism has yet been identified that accounts for the abrupt transition from the genomic stability of normal cells to the instability typical of neoplasia. The opportunity to investigate a specific aspect of this transition has become available with the development of experimental systems to study gene amplification (reviewed in ref. 6 ). Localized amplification of chromosomal segments is a kind of genomic rearrangement seen especially in cells of advanced tumors undergoing malignant progression (7) .
Cytologically, amplification has been detected either as an aberrant chromosomal segment (HSR, homogeneously staining region) or as extrachromosomal nuclear bodies called double-minutes (DMs). In experimental systems and in certain tumors, the HSRs and DMs have been identified as alternative arrangements of the same amplified DNA sequence (reviewed in ref. 6 ). The importance of amplification in tumor progression is underlined by the discovery that some DMs consist of amplified copies of cellular oncogenes-e.g., Ki-ras in the murine adenocortical tumor line Y1 (8) , N-myc in neuroblastomas (9) , and c-myc in HL-60 cells (10) and in certain lung tumors (11) . DMs of unknown sequence or function have been identified in a large number of human and rodent tumors (12) .
Gene amplification was initially discovered in a series of transformed cell lines that had undergone stepwise selection for methotrexate (MTX) resistance (13) . The highly resistant cells contained an abnormally long chromosome with a uniformly staining region, an HSR later shown to consist of many tandem repeats of the gene DHFR coding for dihydrofolate reductase (DHFR; 5,6,7,8-tetrahydrofolate:NADP+ oxidoreductase, EC 1.5.1.3) and flanking regions (6, 14) . Gene amplification has been established as a mechanism of cellular resistance not only to MTX but also to other toxic agents (14, 15) .
Although developmentally regulated transient gene amplification has been described in Drosophila (16) (17) . Cell line 204-Tu is tumor-derived from a thymidine kinase-deficient (TK-) mutant of CHEF/16 (18) . Cells are routinely grown in minimal essential medium alpha (KC Biological, Lenexa, KS) supplemented with 10% fetal bovine serum (J. R. Scientific, Woodland, CA), streptomycin (100 pug/ml), penicillin (100 units/ml), and 2.0 mM glutamine, as described (17) . Selection of MTX-resistant cell lines was carried out during a period when fetal calf serum was very scarce and thus used primarily for maintenance of stocks. The substitute serum that best fit our requirements for growth of CHEF cells was 3% newborn calf serum (Biocell Laboratories) plus 3% horse serum (M. A. Bioproducts, Walkersville, MD). Dialysis of this serum was found to be unnecessary, since MTXresistance levels of cells grown in medium with this serum were very similar to levels expressed by the same cultures grown in the presence of dialyzed fetal bovine serum. After selection and storage of MTX-resistant cell lines, subsequent studies were performed with cells grown in 10% fetal calf serum, either dialyzed (for quantitation of MTX-resistance levels) or undialyzed (for all other studies). The selected populations retained MTX-resistance levels in the presence or absence of the drug.
Cell populations were selected for increasing levels of MTX-resistance as described (19) , with some modifications. At each increment in MTX concentration, cells that were growing well at a given level of drug were passed into each of two or three higher levels by inoculating 106 cells into each 25-cm2 flask. Populations that reached confluence at the highest chosen level of drug then were grown in 75-cm2 flasks and used for the next round of selection. At each step, aliquots were frozen for future study; the date offreezing was taken as the time at which each selection step was completed. To assay the MTX-resistance levels of selected populations, plating efficiencies of cells derived from frozen stocks and grown in medium with 10% fetal bovine serum were determined in medium with MTX (Bristol Laboratories, Syracuse, NY) and 10o dialyzed fetal bovine serum. Although initial selection was in medium with undialyzed newborn calf and horse serum, the resistance levels established by plating efficiencies in medium with dialyzed fetal bovine serum correlated well with the initial assignments.
Plasmids. A plasmid containing mouse DHFR cDNA (pDHFR-11) was obtained from R. T. Schimke (Stanford, Palo Alto, CA), and plasmid pAl containing chicken 8-actin cDNA was obtained from D. Cleveland (Johns Hopkins, Baltimore, MD). Dot Blot Analysis. DNA was extracted as described (20) . High molecular weight cellular DNAs were denatured in 57 mM Tris Cl, pH 7.4/0.2 M NaOH/1 M NaCl/0.1 M sodium citrate at 80°C for 10 min, neutralized with 2 M Tris Cl to pH 7.0, and spotted onto nitrocellulose in a 96-well microsample filtration manifold (Schleicher & Schuell). The filter was hybridized with 32P-labeled nick-translated probes and processed as described (38) .
Chromosome Analysis. For karyotype analysis, 2 x 106 cells were seeded into 75-cm2 flasks containing 10 ml of culture medium, incubated 48-72 hr at 37°C, treated with Colcemid (GIBCO) at 0.05 pmg/ml for 1 hr, and harvested with trypsin. Cells were sedimented by centrifugation, resuspended in hypotonic (0.4%) KCI for 10 min, and fixed in methanol/acetic acid (3:1, vol/vol). Freshly prepared airdried chromosome preparations were stained by trypsinGiemsa banding (21) . The chromosomal constitution of each cell line was determined from analysis of Giemsa-banded karyotypes of 10-20 cells. We use the Chinese hamster chromosome numbering system of Kakati and Sinha (22) , the Giemsa-band-number designation of Stubblefield (23) , and the International System of Cytogenetic Nomenclature (24 Chromosomal Changes in MTX-Resistant Cells. Karyotypes of MTX-resistant cells were examined by G-and C-banding and by in situ hybridization of chromosome spreads with the plasmid pDHFR-11. The effects of MTXselection on the CHEF/18 karyotype are shown in Fig. 4 Left. Even at the resistance level of 0.1 AM MTX, at which only a doubling of DHFR gene copy number was detected, the chromosomes had already undergone severe changes. The Y chromosome was lost, and four marker chromosomes appeared, containing complex rearrangements of fragments from chromosomes 1, 2, and others. In subsequent steps of selection, additional marker chromosomes appeared, leaving few residual chromosomes that could still be identified. Even those appeared abnormal. Novel heterochromatic regions, probably representing amplification, were detected by Cbanding (Fig. 4 Left, karyotype e).
In contrast to these results, the tumorigenic CHEF/16 ( Table 1. selection. Initially, the CHEF/16cells were diploid, and the marker chromosome that appeared at 0.1 AuM MTX later disappeared. At the MTX-resistance level 1 AuM, two marker chromosomes were evident, and they increased in size over the course of selection for MTX-resistance. C-banding revealed the heterochromatic regions present in marker 15 (Fig.  4 Right, karyotype d).
The location of the amplified sequences was determined by in situ hybridization with the DHFR cDNA plasmid (Fig. 5) .
In CHEF/18 cells resistant to 200 AuM MTX, in which a 32-fold amplification of the DHFR gene was present, no amplified sequences could be localized by in situ hybridization. In most cells, radioactive disintegrations were not above background; the cell shown in Fig. 5 Left is exceptional. Since a 32-fold amplification would be detected under our conditions, these results suggest that the amplified sequences were dispersed rather than localized at a single site.
On the contrary, the localization of amplified sequences to a single chromosome was clearly evident in the preparations from CHEF/16 and 204-Tu cells. In CHEF/16 (Fig. 5 Center), the amplified chromosome is marker 15, in which amplification revealed by C-banding is shown in Fig. 4 Right.
The 204-Tu cells contained three marker chromosomes which arose during tumor formation before MTX-selection. These chromosomes were retained during MTX-selection but did not contain detectable amplified DHFR sequences. A new (Fig. 3 ).
tSensitive to 10 nM MTX. (26) . However, the protocol used for CHEF/18 cells was the same as that used for the tumorigenic CHEF cell lines and similar to that employed by other investigators (6) who did not find extensive breakage and rearrangement. Thus, it seems unlikely that the breakage in CHEF/18 chromosomes was a consequence of thymidine starvation.
Proposed molecular mechanisms of DNA amplification discussed in recent reviews (6, 14, 15) have all been based on the events typically seen in transformed rodent cells and first described by Biedler and Spengler (13) These results with a human cell line resemble our findings with CHEF/18 cells, reported here, and are consistent with the known stability of the human genome and relative stability of the CHEF/18 genome. Both of these cell lines are much less susceptible to amplification than the transformed rodent lines used as model systems (6) . The relative stability of the human genome in early neoplasia may account for the clinical observation ofamplified oncogene sequences as a late stage in tumor progression (11) .
In conclusion, the results with CHEF cells support our hypothesis that gene amplification is an expression of genomic instability in neoplastic cells. Localized amplification appears to be tightly regulated in normal cells and may in fact provide an assay for a stable genome vs. a destabilized one. The underlying mechanism that regulates amplification may be part of the normal system by which genomic stability is maintained and which can be upset, for example, by chromosomal breakage and activation of transposable elements (37) . Awareness of the dramatic difference between normal and neoplastic cells in their ability to undergo amplification may lead to rewarding investigations of cancer as a genomic disease.
